Spero Therapeutics Inc (SPRO)

Currency in USD
1.980
+0.130(+7.03%)
Closed·
1.945-0.035(-1.75%)
·
SPRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SPRO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.8502.010
52 wk Range
0.5053.220
Key Statistics
Prev. Close
1.85
Open
1.85
Day's Range
1.85-2.01
52 wk Range
0.505-3.22
Volume
555.41K
Average Volume (3m)
4.52M
1-Year Change
36.53%
Book Value / Share
0.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SPRO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.000
Upside
+102.02%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Spero Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Spero Therapeutics Inc Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of -$0.03 beat -$0.57 forecast; revenue of $14.2M exceeded $11M estimate. Stock rose 7.27% post-earnings.
  • Successful Phase 3 trial for tebipenem HBr positions company for growth in antibiotic treatment market, FDA approval expected 2026.
  • Extended cash runway to 2028, supported by GSK partnership milestone payments. R&D expenses halved to $10.7M.
  • Challenges remain with SPR720 program; management exploring next steps. Analysts maintain 'Hold' with $5 price target.
  • CEO emphasized tebipenem HBr as potential first commercial product from pipeline, highlighting strategic focus on regulatory approval.
Last Updated: 12/08/2025, 22:10
Read Full Transcript

Compare SPRO to Peers and Sector

Metrics to compare
SPRO
Peers
Sector
Relationship
P/E Ratio
−2.1x−1.2x−0.6x
PEG Ratio
0.00−0.050.00
Price/Book
3.4x1.7x2.6x
Price / LTM Sales
2.3x8.2x3.3x
Upside (Analyst Target)
116.2%278.7%38.7%
Fair Value Upside
Unlock28.0%5.1%Unlock

Analyst Ratings

0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 4.000
(+102.02% Upside)

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.03 / -0.57
Revenue / Forecast
14.19M / 11.00M
EPS Revisions
Last 90 days

SPRO Income Statement

People Also Watch

46.03
BMNR
-7.85%
1.940
UAVS
-7.62%
1.690
INVZ
-0.59%
2.000
VOR
-3.85%

FAQ

What Stock Exchange Does Spero Therapeutics Trade On?

Spero Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Spero Therapeutics?

The stock symbol for Spero Therapeutics is "SPRO."

What Is the Spero Therapeutics Market Cap?

As of today, Spero Therapeutics market cap is 111.26M.

What Is Spero Therapeutics's Earnings Per Share (TTM)?

The Spero Therapeutics EPS (TTM) is -0.97.

When Is the Next Spero Therapeutics Earnings Date?

Spero Therapeutics will release its next earnings report on 16 Nov 2025.

From a Technical Analysis Perspective, Is SPRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Spero Therapeutics Stock Split?

Spero Therapeutics has split 0 times.

How Many Employees Does Spero Therapeutics Have?

Spero Therapeutics has 32 employees.

What is the current trading status of Spero Therapeutics (SPRO)?

As of 28 Aug 2025, Spero Therapeutics (SPRO) is trading at a price of 1.98, with a previous close of 1.85. The stock has fluctuated within a day range of 1.85 to 2.01, while its 52-week range spans from 0.51 to 3.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.